| Literature DB >> 27408868 |
Krisana Roysri1, Chanisa Chotipanich2, Vallop Laopaiboon3, Jiraporn Khiewyoo1.
Abstract
OBJECTIVES: Diagnostic nuclear medicine is being increasingly employed in clinical practice with the advent of new technologies and radiopharmaceuticals. The report of the prevalence of a certain disease is important for assessing the quality of that article. Therefore, this study was performed to evaluate the quality of published nuclear medicine articles and determine the frequency of reporting the prevalence of studied diseases.Entities:
Keywords: Diagnostic Nuclear Medicine; QUADAS-2; STARD
Year: 2014 PMID: 27408868 PMCID: PMC4937696
Source DB: PubMed Journal: Asia Ocean J Nucl Med Biol ISSN: 2322-5718
Figure 1The number of articles in each journal
The presence of each item of STARD checklist (%) in the articles of 5 nuclear medicine journals (CNM=Clinical Nuclear Medicine, EJNMMI= European Journal of Nuclear Medicine and molecular imaging, JNC= Journal of Nuclear Cardiology, JNM=Journal of Nuclear Medicine, NMC= Nuclear Medicine Communications)
| CNM | EJNMMI | JNC | JNM | NMC | |
|---|---|---|---|---|---|
| 1. Identify the article as a study of diagnostic accuracy (recommended MeSH headings: sensitivity and specificity) | 23(92.0) | 26(100.0) | 3(100.0) | 20(100.0) | 27(100.0) |
| 2. State the research questions or study aims such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups | 25(100.0) | 26(100.0) | 3(100.0) | 20(100.0) | 27(100.0) |
| 3. The study population: the inclusion and exclusion criteria and setting and locations where data were collected | 25(100.0) | 26(100.0) | 3(100.0) | 20(100.0) | 27(100.0) |
| 4. Participant recruitment: Was recruitment based on presenting symptoms, results of previous tests, or the fact that the participants had received the index tests or the reference standard? | 25(100.0) | 24(92.3) | 3(100.0) | 20(100.0) | 27(100.0) |
| 5. Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in items 3 and 4? If not, specify how the participants were further selected. | 25(100.0) | 25(96.2) | 3(100.0) | 20(100.0) | 27(100.0) |
| 6. Data collection: Was data collection planned before (prospective study) or after (retrospective study) performing index test and reference standard? | 21(84.0) | 25(96.2) | 3(100.0) | 20(100.0) | 26(96.3) |
| 7. The reference standard and its rationale | 24(96.0) | 26(100.0) | 3(100.0) | 20(100.0) | 27(100.0) |
| 8. Mention technical specifications of materials and methods involved including how and when the measurements were taken and/or cite the references for index tests and reference standard | 25(100.0) | 26(100.0) | 3(100.0) | 19(95.0) | 27(100.0) |
| 9. Definition of and rationale for the units, cut-offs, and/or categories of the results of index tests and reference standard | 23 (92.0) | 26 (100.0) | 3 (100.0) | 17 (85.0) | 26 (96.3) |
| 10. The number, training, and expertise of people executing and reading the index tests and reference standard | 18 (72.0) | 21 (80.8) | 3 (100.0) | 9 (45.0) | 16 (59.3) |
| 11. Determine whether or not the readers of the index tests and reference standard were blinded (masked) to the results of other tests; describe other clinical information available to the readers | 12 (48.0) | 19 (73.1) | 2 (66.7) | 9 (45.0) | 16(59.3) |
| 12. Methods for calculating or comparing measures of diagnostic accuracy and statistical methods used to quantify uncertainty (e.g., 95% confidence interval) | 24 (96.0) | 22 (84.0) | 3 (100.0) | 19 (95.0) | 23 (85.2) |
| 13. Methods for calculating test reproducibility, if done | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| 14. The time of performing the study including the beginning and end of recruitment | 15 (60.0) | 16 (61.5) | 2 (66.7) | 13 (65.0) | 21 (77.8) |
| 15. Clinical and demographic characteristics of the study population (at least the patients’ age, gender, and spectrum of presenting symptoms) | 24 (96.0) | 25 (96.2) | 3 (100.0) | 19 (95.0) | 26 (96.3) |
| 16. The number of legible participants, who did or did not undergo the index tests and/or the reference standard; describe why the participants failed to undergo the tests (a flow diagram is strongly recommended) | 24 (96.0) | 23 (88.5) | 2 (66.7) | 17 (85.0) | 25 (92.6) |
| 17. Time interval between the index tests and reference standard, and any treatment administered in between | 9 (36.0) | 13 (50.0) | 2 (66.7) | 9 (45.0) | 15 (55.6) |
| 18. Distribution of the severity of the disease (define the criteria) in those with the target condition and other diagnoses in participants without the target condition | 19 (76.0) | 16 (61.5) | 1 (33.3) | 10 (50.0) | 4 (14.8) |
| 19. Reporting a cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of reference standard; for continuous results, the distribution of the test results by the results of reference standard | 19 (76.0) | 20 (76.9) | 1 (33.3) | 19 (95.0) | 24 (88.9) |
| 20. Any adverse events due to performing the index tests or reference standard | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 3 (11.1) |
| 21. Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g., 95% confidence interval) | 9 (36.0) | 11 (42.3) | 0 (0.0) | 6 (30.0) | 8 (29.6) |
| 22. How indeterminate results, missing data, and outliers of the index tests were handled | 0 (0.0) | 1 (3.8) | 0 (0.0) | 2 (10.0) | 0 (0.0) |
| 23. Estimates of the variability of diagnostic accuracy between subgroups of participants, readers, or centers, if done | 4 (16.0) | 5 (19.2) | 2 (66.7) | 7 (35.0) | 4 (14.8) |
| 24. Estimates of test reproducibility, if done | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 25. Discussing the clinical applicability of the study findings | 25 (100.0) | 26 (100.0) | 3 (100.0) | 20 (100.0) | 27 (100.0) |
The average STARD scores of 5 nuclear medicine journals with the highest impact factors
| Clinical Nuclear Medicine | European Journal of Nuclear Medicine | Journal of Nuclear Cardiology | Journal of Nuclear Medicine | Nuclear Medicine Communications | |
|---|---|---|---|---|---|
| STARD score | 17.0 ±2.2 | 17.2±2.4 | 17.0 ±1.7 | 16.9±3.2 | 16.9±2.1 |
| Methodology (Total=11) | 9.2 ±1.3 | 9.2 ±1.2 | 9.7±0.6 | 8.7 ± 1.2 | 9.0± 1.2 |
| Results and discussion (Total=12) | 5.9±1.3 | 6.0±1.5 | 5.3±2.1 | 6.3±2.2 | 5.8±1.3 |
The results of QUADAS-2 for 5 nuclear medicine journals with the highest impact factors
| Clinical Nuclear Medicine (%) | European Journal of Nuclear Medicine (%) | Journal of Nuclear Cardiology (%) | Journal of Nuclear Medicine (%) | Nuclear Medicine Communications (%) | |||
|---|---|---|---|---|---|---|---|
| Population | Bias | Low | 24 (96.0) | 26 (100.0) | 3 (100.0) | 20 (100.0) | 27 (100.0) |
| High | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| unclear | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Concern | Low | 25 (100.0) | 26 (100.0) | 3 (100.0) | 20 (100.0) | 27 (100.0) | |
| High | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| unclear | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Index test | Bias | Low | 5 (20.0) | 7 (26.9) | 2 (66.7) | 6 (30.0) | 6 (22.2) |
| High | 4 (16.0) | 7 (26.9) | 1 (33.3) | 5 (25.0) | 6 (22.2) | ||
| unclear | 16 (64.0) | 12 (46.1) | 0 (0.0) | 9 (45.0) | 15 (55.6) | ||
| Concern | Low | 13 (52.0) | 12 (46.2) | 3 (100.0) | 14 (70.0) | 21 (77.8) | |
| High | 0 (0.0) | 3 (11.5) | 0 (0.0) | 0 (0.0) | 1 (3.7) | ||
| unclear | 12 (48.0) | 11 (42.3) | 0 (0.0) | 6 (30.0) | 5 (18.5) | ||
| Reference standard | Bias | Low | 10 (40.0) | 10 (38.5) | 3 (100.0) | 11 (55.0) | 10 (37.0) |
| High | 1 (4.0) | 8 (30.8) | 0 (0.0) | 2 (10.0) | 4 (14.8) | ||
| unclear | 14 (56.0) | 8 (30.8) | 0 (0.0) | 7 (35.0) | 13 (48.1) | ||
| Concern | Low | 14 (56.0) | 13 (50.0) | 3 (100.0) | 15 (75.0) | 13 (48.1) | |
| High | 0 (0.0) | 6 (23.1) | 0 (0.0) | 0 (0.0) | 1 (3.7) | ||
| unclear | 11 (44.0) | 7 (26.9) | 0 (0.0) | 5 (25.0) | 13 (48.1) | ||
| Time interval | Low | 9 (36.0) | 10 (38.5) | 3 (100.0) | 9 (45.0) | 8 (29.6) | |
| High | 12 (48.0) | 16 (61.5) | 0 (0.0) | 9 (45.0) | 18 (66.7) | ||
| unclear | 4 (16.0) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 1 (3.7) | ||
Figure 2Risk assessment of population, using QUADAS-2
Figure 5Risk assessment of time interval
The report of disease prevalence and the appropriateness of reference standard
| Journal of Nuclear Medicine (N=20) | European Journal of Nuclear Medicine (N=26) | Clinical Nuclear Medicine (N=25) | Journal of Nuclear Cardiology (N =3) | Nuclear Medicine Communications (N=27) | ||
|---|---|---|---|---|---|---|
| Disease Prevalence Report (%) | 21.0 | 24.0 | 3.8 | 0 | 31.0 | |
| Reference standard | Appropriate (%) | 36.8 | 20.0 | 26.9 | 66.7 | 13.8 |
| Fair (%) | 63.2 | 76.0 | 69.2 | 33.3 | 79.3 | |
| Not appropriate (%) | 5.3 | 8.0 | 0.0 | 0 | 3.4 | |